Featured

2024 was a 'very good period for dealmaking' and Sullivan Street hopes this momentum will continue into 2025.

'We focus on growth not cost cuts. This is a win for all parties. It’s liquidity much faster and easier than an IPO. It’s partnership with a growth investor.'

PAI is optimistic about the new year, with eyes on opportunities for companies in the real economy.

Béla Szigethy and Stewart Kohl: 'Investors remain highly discerning, selective and willing to do more work, dig deeper in diligence, be more patient and demanding, and GPs must respond with enhanced fundraising capacity and improved stewardship.'

‘The market has come towards the sellers, but the sellers have also now agreed to reduce their expectations,’ the Bridgepoint chief investment officer told PE Hub in this NEXUS 2025 preview interview.

VCJ spoke with 10 of our Rising Stars to find out what they are looking forward to, including ongoing specialization within the venture industry and helping their firms become more efficient by using technology.

Montagu Private Equity, Lee Equity Partners and Webster Equity Partners are among the PE firms investing in the cardiology market.

The private equity firm is in the early stages of launching several sale processes.

2025 is likely to be a transitional year for the shift to renewable energy, though strategic M&A processes may well see pause until clarity is known about the Investment Tax Credit and Production Tax Credit.

'We’ve seen several high-profile transactions in life sciences, resulting in big exits for investors in the private and public markets,' said Toby Sykes, managing director of Intermediate Capital Group.